Aytu Biopharma (AYTU) Change in Accured Expenses (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of Change in Accured Expenses data on file, last reported at -$5.9 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 466.27% year-over-year to -$5.9 million in Q1 2026; TTM through Mar 2026 was -$7.1 million, a 291.06% decrease from a year earlier, with the FY2025 full-year figure at $886000.0, up 109.67% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$5.9 million, down from $3.5 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for AYTU reached as high as $8.0 million in Q1 2023 and fell as low as -$14.5 million in Q2 2022.
• Historically, Change in Accured Expenses has averaged -$1.3 million across 5 years, with a median of -$1.6 million in 2025.
• Across the five-year window, Change in Accured Expenses tumbled 574.67% in 2022 and jumped 879.88% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $2.5 million in 2022, then plunged by 48.52% to $1.3 million in 2023, then surged by 474.23% to $7.3 million in 2024, then sank by 52.72% to $3.5 million in 2025, then slumped by 270.31% to -$5.9 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$5.9 million in Q1 2026, $3.5 million in Q4 2025, and -$1.6 million in Q3 2025.